NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announces that a complaint has been filed in the United States District Court for the Central District of California on behalf of investors (the “Class”) who purchased or acquired the securities of Alexandria Real Estate, Inc. (“Alexandria” or the “Company”) (NYSE: ARE) between January 27, 2025 through October 27, 2025, inclusive, alleging violations of the Securities Exchange Act of 1934 aga ...

Alexandria Real Estate Equities, Inc. (ARE) shares dropped 7.28 percent on Wednesday, falling $3.92 to $49.91 after the company announced that its Board of Directors declared a quarterly dividend of $0.72 per share for the fourth quarter 2025 a 45 percent reduction from the prior quarter.The stock is trading at $49.35, compared with a previous close of $53.83. Today's range is between $49.00 and $52.54, with volume at about 2.27 million shares.Alexandria Real Estate Equities' 52-week range is $48.66 to $10 ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Alexandria To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Alexandria between January 27, 2025 and October 27, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- ...

Summary of Alexandria Real Estate Equities 2025 Investor Day Company Overview - **Company**: Alexandria Real Estate Equities (NYSE: ARE) - **Industry**: Life Science Real Estate Core Points and Arguments 1. **Mission and Impact**: Alexandria focuses on advancing human health by providing mission-critical space for life sciences, with approximately 50% of all FDA approvals in the last decade attributed to its tenants [3][34][35] 2. **Market Conditions**: The life science industry is currently facing significant challenges, including a bear market, regulatory changes, and a decline in demand for lab space, with a reported 62% decrease in demand since peak levels in 2021 [4][8][31] 3. **Supply and Demand Dynamics**: The company is navigating an oversupplied market, leading to declining occupancy rates and slower lease-up of new developments [10][44] 4. **Financial Strategy**: Alexandria aims to maintain a strong balance sheet, optimize cash flow, and strategically invest in its mega campuses while reducing capital expenditures [10][12][13] 5. **Regulatory Environment**: The FDA is experiencing leadership turmoil, which has resulted in increased delays in drug approvals, impacting the life science sector [33][34] 6. **Venture Capital Trends**: Venture capital fundraising is at a decade low, affecting the ability of biotech companies to secure funding and grow [31][32] 7. **M&A Activity**: Despite challenges, there is a strong year for mergers and acquisitions as pharmaceutical companies seek new innovations to offset patent expirations [32][33] 8. **Reimbursement Challenges**: The life science industry faces hurdles in reimbursement for novel medicines, with ongoing discussions about drug pricing impacting funding for research and development [36][37][38] Important but Overlooked Content 1. **NIH Funding Issues**: The proposed 15% cap on indirect costs for NIH grants has frozen institutional demand, creating uncertainty for research institutions [29][30] 2. **Market Performance Metrics**: Alexandria's leasing volume in Greater Boston and San Diego significantly outperforms competitors, with 110% and 150% of the next five largest life science real estate owners, respectively [46][49] 3. **Mega Campus Strategy**: Alexandria's proprietary algorithm combines location, innovation, talent, and capital to create a competitive advantage in the life science real estate market [45][46] 4. **Historical Context**: Alexandria has a 30-year history in the life science real estate sector, having pioneered the industry and established a first-mover advantage [45] 5. **Future Opportunities**: The potential for AI and biological discoveries to transform drug development could lead to significant growth in the biotech sector, increasing demand for Alexandria's infrastructure [39][40] Conclusion Alexandria Real Estate Equities is strategically positioned to navigate current industry challenges while leveraging its unique mega campus model to capture future demand in the life sciences sector. The company remains focused on maintaining financial strength and operational excellence amidst a tumultuous market environment.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Viewpoint - Alexandria Real Estate Equities, Inc. announced a quarterly cash dividend of $0.72 per common share for Q4 2025, marking a 45% reduction from the previous quarter's dividend [1] Financial Summary - The dividend is payable on January 15, 2026, to stockholders of record on December 31, 2025 [1] - The decision to reduce the dividend reflects the company's commitment to strengthen its balance sheet, enhancing financial flexibility and preserving approximately $410 million in liquidity annually [1] - The new dividend provides an attractive yield of 5.4% based on the closing stock price on December 1, 2025 [1] Company Overview - Alexandria Real Estate Equities, Inc. is a leading life science REIT, founded in 1994, and is recognized for pioneering the life science real estate niche [1] - The company operates in key life science innovation clusters, including Greater Boston, San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City [1]

Core Viewpoint - Alexandria Real Estate Equities, Inc. is facing a securities class action lawsuit due to alleged failure to disclose material information during the class period, leading to significant financial losses for investors [3]. Group 1: Lawsuit Details - Investors who suffered substantial losses from purchasing Alexandria's securities between January 27, 2025, and October 27, 2025, have until January 26, 2026, to file lead plaintiff applications [1]. - The lawsuit is pending in the United States District Court for the Central District of California [1]. - The case is identified as Warren Hern v. Alexandria Real Estate Equities, Inc., et al., No. 25-cv-11319 [5]. Group 2: Financial Performance - On October 27, 2025, Alexandria disclosed third-quarter financial results for fiscal year 2025 that fell below expectations, including a reduction in full-year 2025 FFO guidance [4]. - The company reported a real estate impairment charge of $323.9 million, with $206 million attributed to its LIC property [4]. - Following this announcement, Alexandria's share price dropped from $77.87 to $62.94, marking a decline of approximately 19% in one day [5]. Group 3: Legal Representation - Kahn Swick & Foti, LLC, a prominent boutique securities litigation law firm, is representing the investors in this case [5]. - The firm has been recognized among the top 10 firms nationally based on total settlement value [5].

NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. (“Alexandria” or the “Company”) (NYSE: ARE).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Alexand ...

NEW YORK--(BUSINESS WIRE)---- $ARE #ARE--Alexandria Real Estate Equities Impairment Charge Triggers Securities Fraud Class Action after Stock Drops Over 19% -- Investors Urged to Contact BFA. ...

LOS ANGELES--(BUSINESS WIRE)--Law Offices of Frank R. Cruz Encourages Alexandria Real Estate Equities, Inc. (ARE) Shareholders To Inquire About Securities Fraud Class Action. ...